Rhythm Pharmaceuticals, Inc. (RYTM) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Boston, MA, United States. El CEO actual es David Meeker.
RYTM tiene fecha de IPO 2017-10-09, 283 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $5.96B.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of therapeutics for rare genetic diseases of obesity. The company's lead product, IMCIVREE, is a melanocortin-4 receptor agonist approved for treating obesity caused by POMC, PCSK1, and LEPR deficiencies, as well as Bardet-Biedl and Alström syndromes. Rhythm is also advancing setmelanotide through Phase II clinical trials for multiple rare genetic obesity indications, including heterozygous POMC or LEPR deficiency, SH2B1 deficiency, MC4 receptor deficiency, and Smith-Magenis syndrome. Founded in 2008 and formerly known as Rhythm Metabolic, Inc., the company collaborates with leading clinical research organizations to advance its pipeline and address significant unmet medical needs in rare genetic obesity.
